U.S. CDC expands use of bivalent COVID vaccines for kids as young as 6 months
Reuters
Published Dec 09, 2022 02:10PM ET
(Reuters) - The U.S. Centers for Disease Control and Prevention (CDC) on Friday expanded the use of COVID-19 vaccines that target both the original coronavirus and Omicron sub-variants to include children aged 6 months through 5 years.
The development comes a day after the U.S. Food and Drug Administration authorized the updated shots from Moderna (NASDAQ:MRNA) as well as Pfizer (NYSE:PFE) and its partner BioNTech for use in children as young as 6 months.
Children aged 6 months through 5 years will now be eligible to get a Moderna bivalent booster 2 months after their final primary vaccination dose for COVID-19.
Pfizer/BioNTech's updated vaccine for children aged 6 months through 4 years can be given only as the third dose for those who are yet to complete their primary COVID-19 vaccinations.
Vaccines for young children in the United States were only approved in June this year, making them the last group to become eligible for vaccination.
Data from the CDC shows only 2.9% children under the age of 2 years, and less than 5% of children aged 2 to 4 years, who are eligible have completed their primary vaccination series as of Dec. 7.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.